Genfit (XUP) Stock Overview
Engages in the research and development of medicines and diagnostic solutions in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
XUP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €12.86 |
| 52 Week High | €12.86 |
| 52 Week Low | €3.01 |
| Beta | 1.1 |
| 1 Month Change | 41.63% |
| 3 Month Change | 71.93% |
| 1 Year Change | 294.00% |
| 3 Year Change | 258.72% |
| 5 Year Change | 293.75% |
| Change since IPO | -38.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| XUP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 27.8% | -0.1% | 4.3% |
| 1Y | 294.0% | 17.2% | 2.9% |
Return vs Industry: XUP exceeded the German Biotechs industry which returned 16.8% over the past year.
Return vs Market: XUP exceeded the German Market which returned 2.9% over the past year.
Price Volatility
| XUP volatility | |
|---|---|
| XUP Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: XUP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XUP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 188 | M. Prigent | www.genfit.com |
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum.
Genfit S.A. Fundamentals Summary
| XUP fundamental statistics | |
|---|---|
| Market cap | €670.32m |
| Earnings (TTM) | -€85.97m |
| Revenue (TTM) | €65.43m |
Is XUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XUP income statement (TTM) | |
|---|---|
| Revenue | €65.43m |
| Cost of Revenue | €0 |
| Gross Profit | €65.43m |
| Other Expenses | €151.40m |
| Earnings | -€85.97m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 29, 2026
| Earnings per share (EPS) | -1.72 |
| Gross Margin | 100.00% |
| Net Profit Margin | -131.38% |
| Debt/Equity Ratio | -668.7% |
How did XUP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 19:23 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genfit S.A. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Arnaud Cadart | CIC Market Solutions (ESN) |
| Alethia Young | Deutsche Bank |